FDA
-
-
-
-
-
-
-
Corcept reports survival benefit in ALS drug trial after two years
-
-
-
-
-
-
-
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorliâ„¢ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in P
-
-
-
-
-
-
-
DEADLINE ALERT for KD, PYPL, SMR, and CORT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
-
-
-
-
-
-
-
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
-
-
-
-
-
-
-
Corcept shares drop 50% after FDA rejects drug application
-
-
-
-
-
-
-
DEADLINE ALERT for KD, PYPL, SMR, and CORT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
-
-
-
-
-
-
-
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
-
322,945 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

